Start here
Overview
Clinical references note that Alpha-1 antitrypsin deficiency (AAT deficiency, or AATD) is an inherited condition that raises your risk for lung and liver disease. In practice, if you have this condition, your body doesn't make enough alpha-1 antitrypsin (AAT). Evidence summaries report that AAT is made by your liver. This overview explains the usual pattern of Alpha-1-antitrypsin deficiency; it cannot determine whether one individual has the condition.
- Clinical references note that Alpha-1 antitrypsin deficiency (AAT deficiency, or AATD) is an inherited condition that raises your risk for lung and liver disease. In practice, if you have this condition, your body doesn't make enough alpha-1 antitrypsin (AAT). Evidence summaries report that AAT is made by your liver. This overview explains the usual pattern of Alpha-1-antitrypsin deficiency; it cannot determine whether one individual has the condition.
- Clinical references note that your clinician may test you for AAT deficiency if you have: Symptoms of AAT shortage A condition that could be related to AAT deficiency Relatives who have AAT shortage Relatives who have a lung or liver disease that could be related to AAT deficiency AAT deficiency in babies often affects the liver. In practice, your baby may need AAT testing if he or she has signs of liver disease such as jaundice or abnormal liver enzyme tests. Evidence summaries report that a blood test can check the level of AAT protein in your blood. For patients and families, an important point is that if the level is lower than normal, it is likely that you have AAT deficiency. Identifying Alpha-1-antitrypsin deficiency starts with the clinical pattern and a focused examination. A clinician chooses tests to answer a specific question, then interprets results alongside age, medicines, family history, exposures, and other conditions. No single investigation is appropriate for every person.
- Evidence summaries report that no curative treatment is currently established for AAT deficiency, but there are treatments to help with the symptoms and slow the lung damage it causes. For patients and families, an important point is that treatment options may include: Inhaled medicines to help you breathe better. Clinical references note that Augmentation therapy, which is a lifelong treatment. In practice, it raises the levels of the AAT protein in your lungs, using ATT protein taken from the blood of donors. Care for Alpha-1-antitrypsin deficiency depends on its cause, severity, organs involved, other health conditions, and the person's goals. Options can range from observation and symptom support to medicines, procedures, rehabilitation, or specialist follow-up. The safest plan is individualized; prescribed care should not be changed because another person had a different experience.
Do not wait for a website to decide
- Call local emergency services for collapse, new confusion, major breathing difficulty, uncontrolled bleeding, or symptoms that are severe and rapidly worsening.
- Seek prompt professional assessment when symptoms are new, persistent, or clearly worsening.
People can experience it differently
What symptoms can occur?
Evidence summaries report that some those who have AAT deficiency do not have any symptoms. For patients and families, an important point is that for those who do, symptoms usually appear in people between 20 and 50 years old. Clinical references note that these possible symptoms are: Wheezing. In practice, possible symptoms include shortness of breath, especially after exercise Chronic cough with phlegm (mucus) Repeated respiratory infections such as colds and the flu. Symptoms can overlap with other illnesses, and their absence does not always rule the condition out.
Risk does not equal certainty
Causes and risk factors
What is known about the cause
Clinical references note that AAT deficiency is a genetic disorder. In practice, That means it's caused by changes in your genes, which can also be called gene variants or mutations. Evidence summaries report that your genes carry information that controls what you look like and how your body works. For patients and families, an important point is that AAT deficiency can result from changes in the SERPINA1 gene, which carries instructions for making the AAT protein. The cause of Alpha-1-antitrypsin deficiency may be established, multifactorial, or still uncertain. Biological mechanisms, inherited factors, infections, exposures, medicines, and related health conditions are considered only when they fit the evidence. A general description should not be used to assign a personal cause.
Factors associated with higher risk
Evidence summaries report that Alpha-1 antitrypsin deficiency (AAT deficiency, or AATD) is an inherited condition that raises your risk for lung and liver disease. For patients and families, an important point is that people living with this disorder have a higher risk of getting lung disease or liver damage before the age of 45. Clinical references note that In these cases, this means you are at slightly higher likelihood of developing lung disease, especially if you have other risk factors, such as being a smoker. Factors linked with Alpha-1-antitrypsin deficiency differ by subtype and population. A clinician may consider age, family history, relevant exposures, medicines, and related conditions, but the importance of each factor varies. Risk changes probability; it does not confirm a diagnosis or predict one person's course.
Risk is not a diagnosis
Who is more likely to be affected?
Evidence summaries report that Alpha-1 antitrypsin deficiency (AAT deficiency, or AATD) is an inherited condition that raises your risk for lung and liver disease. For patients and families, an important point is that people living with this disorder have a higher risk of getting lung disease or liver damage before the age of 45. Clinical references note that In these cases, this means you are at slightly higher likelihood of developing lung disease, especially if you have other risk factors, such as being a smoker. Factors linked with Alpha-1-antitrypsin deficiency differ by subtype and population. A clinician may consider age, family history, relevant exposures, medicines, and related conditions, but the importance of each factor varies. Risk changes probability; it does not confirm a diagnosis or predict one person's course.
Tests answer specific questions
Common tests and what they show
- Clinical assessment
Clinical references note that your clinician may test you for AAT deficiency if you have: Symptoms of AAT shortage A condition that could be related to AAT deficiency Relatives who have AAT shortage Relatives who have a lung or liver disease that could be related to AAT deficiency AAT deficiency in babies often affects the liver. In practice, your baby may need AAT testing if he or she has signs of liver disease such as jaundice or abnormal liver enzyme tests. Evidence summaries report that a blood test can check the level of AAT protein in your blood. For patients and families, an important point is that if the level is lower than normal, it is likely that you have AAT deficiency. Identifying Alpha-1-antitrypsin deficiency starts with the clinical pattern and a focused examination. A clinician chooses tests to answer a specific question, then interprets results alongside age, medicines, family history, exposures, and other conditions. No single investigation is appropriate for every person.
- Purpose and limits of testing
Tests should confirm a working diagnosis, assess severity, identify complications, or rule out an important alternative. Not every person needs every available investigation, and a result must be interpreted in context.
Clinical assessment
How is it diagnosed?
Clinical references note that your clinician may test you for AAT deficiency if you have: Symptoms of AAT shortage A condition that could be related to AAT deficiency Relatives who have AAT shortage Relatives who have a lung or liver disease that could be related to AAT deficiency AAT deficiency in babies often affects the liver. In practice, your baby may need AAT testing if he or she has signs of liver disease such as jaundice or abnormal liver enzyme tests. Evidence summaries report that a blood test can check the level of AAT protein in your blood. For patients and families, an important point is that if the level is lower than normal, it is likely that you have AAT deficiency. Identifying Alpha-1-antitrypsin deficiency starts with the clinical pattern and a focused examination. A clinician chooses tests to answer a specific question, then interprets results alongside age, medicines, family history, exposures, and other conditions. No single investigation is appropriate for every person.
Professional assessment matters
What else can look similar?
Several disorders can resemble Alpha-1-antitrypsin deficiency, and the useful comparison depends on the symptom pattern, age, timing, examination, medicines, exposures, and test findings. Similarity in a search result is not enough to distinguish them. A clinician should prioritize alternatives that are common, treatable, or dangerous to miss, then select only the investigations likely to change care.
Classification can guide care
Types, severity, or stages
Some people with Alpha-1-antitrypsin deficiency are classified by cause, clinical type, severity, affected body system, or stage. These labels can guide testing, treatment, monitoring, and prognosis, but they are not interchangeable. Ask which classification applies, what evidence supports it, and whether it may change as more information becomes available.
Shared decisions
What are the treatment options?
Evidence summaries report that no curative treatment is currently established for AAT deficiency, but there are treatments to help with the symptoms and slow the lung damage it causes. For patients and families, an important point is that treatment options may include: Inhaled medicines to help you breathe better. Clinical references note that Augmentation therapy, which is a lifelong treatment. In practice, it raises the levels of the AAT protein in your lungs, using ATT protein taken from the blood of donors. Care for Alpha-1-antitrypsin deficiency depends on its cause, severity, organs involved, other health conditions, and the person's goals. Options can range from observation and symptom support to medicines, procedures, rehabilitation, or specialist follow-up. The safest plan is individualized; prescribed care should not be changed because another person had a different experience.
Looking beyond today's visit
Outlook and follow-up
The outlook for Alpha-1-antitrypsin deficiency varies with cause, severity, age at onset, organs involved, other health conditions, access to care, and response to treatment. Population averages cannot forecast one person's result. A more useful discussion sets measurable goals, identifies complications worth monitoring, and agrees on a date to reassess the plan.
Recognizing important change
Possible complications
Potential complications of Alpha-1-antitrypsin deficiency depend on the disease mechanism, severity, delay before treatment, and effects of therapy. Follow-up aims to identify important change early without testing for every theoretical problem. Ask which two or three complications are most relevant, what warning signs they cause, and whether scheduled examination or laboratory monitoring is needed.
Practical support
Self-management
For Alpha-1-antitrypsin deficiency, use the monitoring and follow-up plan agreed with the clinical team. Keep an accurate medicine list, note possible side effects, and record meaningful changes in symptoms or daily function. Clinical references note that it helps protect your lungs from inflammation and irritating substances you might breathe in, such as smoke. In practice, Prevent your liver from making any AAT. Evidence summaries report that Affect the shape of the AAT protein so that it can't move out of your liver to protect your lungs. Not every case of Alpha-1-antitrypsin deficiency can be prevented. Where modifiable risks or screening options exist, a clinician can help decide which steps are relevant. Appropriate follow-up and early review of new problems can reduce avoidable harm. Home observations are most useful when they support a clinical decision; repeated checking without a plan can increase anxiety and may still miss important change.
Long-term health
Living with the condition
Living with Alpha-1-antitrypsin deficiency may affect energy, sleep, mobility, school, work, relationships, or emotional wellbeing, although the impact varies widely. Tell the care team what has become difficult rather than reporting test values alone. Ask which activities are safe, what support is available, and how progress will be measured. Reliable peer support can reduce isolation, but another person's diagnosis or treatment should not be copied as a personal plan.
Practical, evidence-based choices
Food and nutrition
There is no universal food plan that cures Alpha-1-antitrypsin deficiency. Nutrition advice should reflect the condition, medicines, swallowing or digestive symptoms, kidney and liver function, allergies, weight goals, culture, and access to food. Avoid restrictive diets or supplements promoted as substitutes for diagnosis or treatment; discuss any product that could interact with prescribed care.
Advice may need adapting
Children, pregnancy, and older adults
Children, older adults, pregnant or breastfeeding people, and those with kidney, liver, immune, developmental, or multiple health conditions may experience Alpha-1-antitrypsin deficiency differently. Test ranges, medicine doses, side-effect risks, and thresholds for urgent review can change in these groups. General information should therefore be checked against advice from a suitably qualified professional.
Separating evidence from assumptions
Common misconceptions
- One symptom or online checklist can prove Alpha-1-antitrypsin deficiency.
Symptoms often overlap across conditions. Diagnosis depends on context, examination, and appropriate testing.
- A treatment that helped another person is automatically safe for me.
Benefits, risks, doses, and monitoring depend on the individual, other conditions, and medicines.
Use appointment time well
Preparing for care
Before an appointment about Alpha-1-antitrypsin deficiency, write down when the problem began, how it has changed, what makes it better or worse, and how it affects ordinary activities. Bring previous reports, a full list of medicines and supplements, allergies, relevant family history, and two or three priorities. Ask what evidence supports the working diagnosis, which alternatives remain possible, what each test could change, and when follow-up should occur.
Care conversations
Questions to ask a health professional
- What findings support this diagnosis, and what important alternatives remain?
- Which tests are most likely to change the next decision?
- What are the realistic benefits, risks, and alternatives for each care option?
- Which changes require routine contact, prompt review, or emergency help?
Questions people often ask
10 common questions
What does Alpha-1-antitrypsin deficiency mean?
Clinical references note that Alpha-1 antitrypsin deficiency (AAT deficiency, or AATD) is an inherited condition that raises your risk for lung and liver disease. In practice, if you have this condition, your body doesn't make enough alpha-1 antitrypsin (AAT). Evidence summaries report that AAT is made by your liver. This overview explains the usual pattern of Alpha-1-antitrypsin deficiency; it cannot determine whether one individual has the condition.
What symptoms can occur with Alpha-1-antitrypsin deficiency?
Evidence summaries report that some those who have AAT deficiency do not have any symptoms. For patients and families, an important point is that for those who do, symptoms usually appear in people between 20 and 50 years old. Clinical references note that these possible symptoms are: Wheezing. In practice, possible symptoms include shortness of breath, especially after exercise Chronic cough with phlegm (mucus) Repeated respiratory infections such as colds and the flu. Symptoms can overlap with other illnesses, and their absence does not always rule the condition out.
What causes Alpha-1-antitrypsin deficiency?
Clinical references note that AAT deficiency is a genetic disorder. In practice, That means it's caused by changes in your genes, which can also be called gene variants or mutations. Evidence summaries report that your genes carry information that controls what you look like and how your body works. For patients and families, an important point is that AAT deficiency can result from changes in the SERPINA1 gene, which carries instructions for making the AAT protein. The cause of Alpha-1-antitrypsin deficiency may be established, multifactorial, or still uncertain. Biological mechanisms, inherited factors, infections, exposures, medicines, and related health conditions are considered only when they fit the evidence. A general description should not be used to assign a personal cause.
Who may be more likely to develop Alpha-1-antitrypsin deficiency?
Evidence summaries report that Alpha-1 antitrypsin deficiency (AAT deficiency, or AATD) is an inherited condition that raises your risk for lung and liver disease. For patients and families, an important point is that people living with this disorder have a higher risk of getting lung disease or liver damage before the age of 45. Clinical references note that In these cases, this means you are at slightly higher likelihood of developing lung disease, especially if you have other risk factors, such as being a smoker. Factors linked with Alpha-1-antitrypsin deficiency differ by subtype and population. A clinician may consider age, family history, relevant exposures, medicines, and related conditions, but the importance of each factor varies. Risk changes probability; it does not confirm a diagnosis or predict one person's course.
How do clinicians identify Alpha-1-antitrypsin deficiency?
Clinical references note that your clinician may test you for AAT deficiency if you have: Symptoms of AAT shortage A condition that could be related to AAT deficiency Relatives who have AAT shortage Relatives who have a lung or liver disease that could be related to AAT deficiency AAT deficiency in babies often affects the liver. In practice, your baby may need AAT testing if he or she has signs of liver disease such as jaundice or abnormal liver enzyme tests. Evidence summaries report that a blood test can check the level of AAT protein in your blood. For patients and families, an important point is that if the level is lower than normal, it is likely that you have AAT deficiency. Identifying Alpha-1-antitrypsin deficiency starts with the clinical pattern and a focused examination. A clinician chooses tests to answer a specific question, then interprets results alongside age, medicines, family history, exposures, and other conditions. No single investigation is appropriate for every person.
How is Alpha-1-antitrypsin deficiency usually treated or managed?
Evidence summaries report that no curative treatment is currently established for AAT deficiency, but there are treatments to help with the symptoms and slow the lung damage it causes. For patients and families, an important point is that treatment options may include: Inhaled medicines to help you breathe better. Clinical references note that Augmentation therapy, which is a lifelong treatment. In practice, it raises the levels of the AAT protein in your lungs, using ATT protein taken from the blood of donors. Care for Alpha-1-antitrypsin deficiency depends on its cause, severity, organs involved, other health conditions, and the person's goals. Options can range from observation and symptom support to medicines, procedures, rehabilitation, or specialist follow-up. The safest plan is individualized; prescribed care should not be changed because another person had a different experience.
Can Alpha-1-antitrypsin deficiency be prevented or its risks reduced?
Clinical references note that it helps protect your lungs from inflammation and irritating substances you might breathe in, such as smoke. In practice, Prevent your liver from making any AAT. Evidence summaries report that Affect the shape of the AAT protein so that it can't move out of your liver to protect your lungs. Not every case of Alpha-1-antitrypsin deficiency can be prevented. Where modifiable risks or screening options exist, a clinician can help decide which steps are relevant. Appropriate follow-up and early review of new problems can reduce avoidable harm.
What should I record between appointments?
Keep a short dated record of symptoms, functional impact, medicines and side effects, relevant measurements, and questions. A consistent summary is usually more useful than a large amount of unstructured information.
When should someone with possible Alpha-1-antitrypsin deficiency seek urgent help?
Use the warning signs near the top of this guide and any personal emergency plan. Severe new symptoms, rapid deterioration, collapse, confusion, major breathing difficulty, uncontrolled bleeding, or inability to remain safe require urgent assessment.
How can I make the next appointment more useful?
Before an appointment about Alpha-1-antitrypsin deficiency, write down when the problem began, how it has changed, what makes it better or worse, and how it affects ordinary activities. Bring previous reports, a full list of medicines and supplements, allergies, relevant family history, and two or three priorities. Ask what evidence supports the working diagnosis, which alternatives remain possible, what each test could change, and when follow-up should occur.
Editorial boundaries
About this guide
Maintained by whocure content team
Purpose Health education and appointment preparation; not individual diagnosis or treatment.
Language status English content is maintained separately from the Chinese edition.